Literature DB >> 1774338

Levels of cytokines in plasma during Plasmodium falciparum malaria attacks.

P Ringwald1, F Peyron, J P Vuillez, J E Touze, J Le Bras, P Deloron.   

Abstract

The variation of levels of tumor necrosis factor, granulocyte-macrophage colony-stimulating factor, gamma interferon, neopterin, and interleukin-2 receptors in plasma were monitored in 16 patients presenting with an acute Plasmodium falciparum malaria attack. Relations among cytokine levels and between cytokine levels and hematological and parasitological data were assessed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774338      PMCID: PMC270266          DOI: 10.1128/jcm.29.9.2076-2078.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Increased levels of released interleukin-2 receptors in Plasmodium falciparum malaria.

Authors:  P Nguyen-Dinh; A E Greenberg
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

2.  Immunological alterations in uncomplicated Plasmodium falciparum malaria. Relationship between parasitaemia and indicators of macrophage activation.

Authors:  P G Kremsner; H Feldmeier; G M Zotter; R Jansen-Rosseck; W Graninger; R M Rocha; U Bienzle
Journal:  Acta Trop       Date:  1989-10       Impact factor: 3.112

3.  Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria.

Authors:  P Deloron; J P Lepers; P Coulanges
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

4.  The dependence of cell-mediated immune activation in malaria on age and endemicity.

Authors:  G Reibnegger; D Fuchs; A Hausen; E Schmutzhard; E R Werner; H Wachter
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

5.  Interleukin 2 receptor in patients with localized and systemic parasitic diseases.

Authors:  O Josimovic-Alasevic; H Feldmeier; K Zwingenberger; G Harms; H Hahn; M Shrisuphanunt; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

6.  TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria.

Authors:  D Kwiatkowski; A V Hill; I Sambou; P Twumasi; J Castracane; K R Manogue; A Cerami; D R Brewster; B M Greenwood
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

7.  Tumor necrosis factor and disease severity in children with falciparum malaria.

Authors:  G E Grau; T E Taylor; M E Molyneux; J J Wirima; P Vassalli; M Hommel; P H Lambert
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

  7 in total
  15 in total

1.  Kinetics of lymphocyte subsets from peripheral blood during a Plasmodium falciparum malaria attack.

Authors:  C Chougnet; S Tallet; P Ringwald; P Deloron
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

2.  The natural killer complex regulates severe malarial pathogenesis and influences acquired immune responses to Plasmodium berghei ANKA.

Authors:  Diana S Hansen; Krystal J Evans; Marthe C D'Ombrain; Nicholas J Bernard; Adrienne C Sexton; Lynn Buckingham; Anthony A Scalzo; Louis Schofield
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

3.  Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria.

Authors:  J Riopel; M Tam; K Mohan; M W Marino; M M Stevenson
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Splenic Innate B1 B Cell Plasmablasts Produce Sustained Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 Cytokines during Murine Malaria Infections.

Authors:  Shu Shien Chin; Laurent Chorro; John Chan; Grégoire Lauvau
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

5.  Genetic variation in CSF2 (5q31.1) is associated with longitudinal susceptibility to pediatric malaria, severe malarial anemia, and all-cause mortality in a high-burden malaria and HIV region of Kenya.

Authors:  Lily E Kisia; Qiuying Cheng; Evans Raballah; Elly O Munde; Benjamin H McMahon; Nick W Hengartner; John M Ong'echa; Kiprotich Chelimo; Christophe G Lambert; Collins Ouma; Prakasha Kempaiah; Douglas J Perkins; Kristan A Schneider; Samuel B Anyona
Journal:  Trop Med Health       Date:  2022-06-25

6.  Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea.

Authors:  Leanne J Robinson; Marthe C D'Ombrain; Danielle I Stanisic; Jack Taraika; Nicholas Bernard; Jack S Richards; James G Beeson; Livingstone Tavul; Pascal Michon; Ivo Mueller; Louis Schofield
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

7.  Functional roles for C5a and C5aR but not C5L2 in the pathogenesis of human and experimental cerebral malaria.

Authors:  Hani Kim; Laura K Erdman; Ziyue Lu; Lena Serghides; Kathleen Zhong; Aggrey Dhabangi; Charles Musoke; Craig Gerard; Christine Cserti-Gazdewich; W Conrad Liles; Kevin C Kain
Journal:  Infect Immun       Date:  2013-11-04       Impact factor: 3.441

Review 8.  Role of TLRs/MyD88 in host resistance and pathogenesis during protozoan infection: lessons from malaria.

Authors:  Catherine Ropert; Bernardo S Franklin; Ricardo T Gazzinelli
Journal:  Semin Immunopathol       Date:  2007-12-11       Impact factor: 9.623

9.  Treatment of murine cerebral malaria by artemisone in combination with conventional antimalarial drugs: antiplasmodial effects and immune responses.

Authors:  W Armand Guiguemde; Nicholas H Hunt; Jintao Guo; Annael Marciano; Richard K Haynes; Julie Clark; R Kiplin Guy; Jacob Golenser
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

10.  The neuropathology of fatal cerebral malaria in malawian children.

Authors:  Katerina Dorovini-Zis; Kristopher Schmidt; Hanh Huynh; Wenjiang Fu; Richard O Whitten; Dan Milner; Steve Kamiza; Malcolm Molyneux; Terrie E Taylor
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.